Quantcast

Latest Organofluorides Stories

2014-05-06 16:32:22

Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning TITUSVILLE, N.J., May 6, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the results of the company's schizoaffective relapse prevention study of once-monthly atypical long-acting antipsychotic INVEGA(®) SUSTENNA(® )(paliperidone palmitate). The trial found INVEGA(®) SUSTENNA(®) met its primary endpoint of delayed time to and reduced risk of...

2014-05-05 23:02:07

The Firm is investigating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statin. New York, New York (PRWEB) May 05, 2014 Lipitor lawsuits (http://www.thelipitorlawsuit.com/) alleging a link between the use of the statin medication and the development of Type 2 diabetes continue to move forward in courts throughout the U.S., Bernstein Liebhard LLP reports. According to an Order issued on April 30, 2014, U.S....

2014-05-05 08:29:33

First prospective, randomized clinical trial to reflect context of "real world" issues in treating schizophrenia, including recent incarceration and substance abuse TITUSVILLE, N.J., May 5, 2014 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced the results of its landmark PRIDE (Paliperidone Palmitate Research In Demonstrating Effectiveness) trial. PRIDE is the first prospective, randomized clinical trial to compare schizophrenia medications within the context of many...

2014-05-02 12:23:31

DALLAS, May 2, 2014 /PRNewswire/ -- New report "Polyvinylidene Fluoride (PVDF) Market by End User Industry (Chemical Processing, Construction, New Energies, and Oil & Gas), & by Application (Pipes, Coatings, Fittings, Sheets, Films, Tubes, Powder, Membranes, & Cables) - Trends Forecasts to 2019" by MarketsandMarkets, analyzes the global PVDF Market with respect to market drivers, opportunities, and trends in different regions. Browse more than 99 market data...

2014-05-01 20:24:06

Ceritinib (brand name Zykadia(TM)) will be used for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib (brand name Xalkori(TM)) WASHINGTON, May 1, 2014 /PRNewswire-USNewswire/ -- LUNGevity Foundation applauds the FDA approval of Zykadia(TM) for the subset of anaplastic lymphoma kinase-positive (ALK+) patients with advanced cases of non-small cell lung cancer who have...

2014-04-30 23:21:01

Court documents indicate some men who filed Risperdal lawsuits involving gynecomastia allege they were forced to undergo liposuction or mastectomies to remove excess breast tissue, and suffered severe psychological and emotional distress, reports Wright & Schulte LLC. New York, NY (PRWEB) April 30, 2014 Wright & Schulte LLC, an experienced personal injury law firm representing plaintiffs in Risperdal gynecomastia lawsuits, notes that the First Judicial District Court of...

2014-04-30 08:24:10

DUBLIN, April 30, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/r9mnq5/global_and ) has announced the addition of the "Global and Chinese PCTFE Industry Report 2014" [http://www.researchandmarkets.com/research/r9mnq5/global_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The Global and Chinese Polychlorotrifluoroethene (PCTFE) Industry Report 2014 is a professional and in-depth...

2014-04-29 16:32:08

- Zykadia (ceritinib) demonstrated an overall response rate of 54.6% in patients with ALK+ metastatic NSCLC who have no other treatment option[1] EAST HANOVER, N.J., April 29, 2014 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Zykadia(TM) (ceritinib, previously known as LDK378) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are...

2014-04-28 16:31:49

DUBLIN, April 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration (FDA) challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex(®) (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. Actavis maintains that the FDA improperly awarded sole exclusivity on generic Celebrex(®) to...

2014-04-26 23:01:46

A Recent Decision by The Arkansas Supreme Court Not To Reconsider Risperdal Lawsuit Judgement In A Recent Medicaid Fraud Lawsuit Has Many Concerned Columbus, OH (PRWEB) April 26, 2014 The Risperdal lawsuit lawyers at Wright & Schulte LLC are concerned with the recent decision by the Arkansas Supreme Court not to reconsider its reversal of a $1.2 billion judgement against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals Inc., the makers of the antipsychotic drug...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.